Mayo Clinic Laboratories is adjusting a number of its autoimmune profiles by removing certain antibodies from those profiles. In this "Test in Focus" episode of the "Answers From the Lab" podcast, Andrew McKeon, M.B., B.Ch., M.D., explains the rationale behind the test updates.

"These are not radical changes by any means. This is something that's been evolving over time," Dr. McKeon says. "We've collected data to drill down on the significance of test results in different phenotypes. Based on that, we're recalibrating our profiles to make sure what's in there is of the highest clinical utility for our providers." Listen to learn more from Dr. McKeon about the specifics of the autoimmune profile updates, and how the changes will streamline testing and enhance test interpretation.

Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

The latest from Test in Focus

Updates Streamline Autoimmune Neurology Testing: Anastasia Zekeridou, M.D., Ph.D.

June 11, 2024

Anastasia Zekeridou, M.D., Ph.D., explains how Mayo Clinic Laboratories' updated panels and methodology boost the accuracy and efficiency of testing for three autoimmune neurology biomarkers. Early diagnosis is key to managing debilitating conditions associated with these antibodies.

Tests Aid Diagnosis of Cancer-Associated Neurological Disorders: Divyanshu Dubey, M.B.B.S.

June 4, 2024

Divyanshu Dubey, M.B.B.S., explains how Mayo Clinic Laboratories' unique PDE10A and TRIM46 tests facilitate the management of central nervous system disorders triggered by cancers. Early diagnosis and treatment are important for managing disabling neurological symptoms and malignancy.

New Panels Help Find Cause of Rapidly Progressive Dementia: Gregg Day, M.D.

May 14, 2024

Rapidly progressive dementia (RPD) is an umbrella term covering many devasting conditions, including Creutzfeldt-Jakob disease (CJD). Gregory (Gregg) Day, M.D., explains how Mayo Clinic Laboratories' unique RPD evaluation and new CJD test help pinpoint diagnosis, to guide prognosis and treatment decisions.

View MoreView Less